Literature DB >> 1326003

Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

J D Reveille1, E Durban, M J MacLeod-St Clair, R Goldstein, R Moreda, R D Altman, F C Arnett.   

Abstract

Previous studies in Caucasians with progressive systemic sclerosis (PSS) have suggested associations of antitopoisomerase I (antitopo I) autoantibodies with either serologically defined HLA-DR2 or DR5. To better define class II HLA associations with the antitopo I response, 161 PSS patients (132 Caucasians and 29 American blacks) were studied for antitopo I autoantibodies by immunodiffusion and immunoblotting, and their HLA-DRB1, DRB3, DQA1, and DQB1 alleles were determined by restriction fragment length polymorphic analysis and DNA oligotyping. Among Caucasians with antitopo I, HLA-DR5(DRB1*1101-*1104), DRB3*0202 and DQw3 (DQw7,8,9) were significantly increased in frequency. In American blacks, however, only HLA-DQB1*0301(DQw7) was significantly increased. The presence of HLA-DQB1*0301(DQw7) and other HLA-DQB1 alleles bearing the uncharged polar amino acid residue tyrosine at position 30 of the outermost domain was found in all antitopo I-positive Caucasian PSS patients compared with 66% of antitopo I-negative PSS patients (pc = 0.007) and 70% of normal controls (pc = 0.008), as well as all antitopo I-positive black patients. The association with HLA-DQB1 was independent of HLA-DR5(DRB1*1101-*1104) or any other HLA-DRB1, DRB3, or DQA1 alleles. Alternative or additional candidate epitopes for this autoimmune response include alanine at position 38 and threonine at position 77 of these same DQB1 alleles. These data suggest that genetic predisposition to the antitopo I response in PSS is associated most closely with the HLA-DQB1 locus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326003      PMCID: PMC329953          DOI: 10.1172/JCI115974

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  HLA-DR-DQ haplotypes defined by restriction fragment analysis. Correlation to serology.

Authors:  B Carlsson; J Wallin; J Böhme; E Möller
Journal:  Hum Immunol       Date:  1987-10       Impact factor: 2.850

2.  A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DQ alleles, including DRw10.

Authors:  J L Bidwell; E A Bidwell; D A Savage; D Middleton; P T Klouda; B A Bradley
Journal:  Transplantation       Date:  1988-03       Impact factor: 4.939

3.  Molecular mapping of class II polymorphisms in the human major histocompatibility complex. I. DR beta.

Authors:  J I Bell; D Denney; A MacMurray; L Foster; D Watling; H O McDevitt
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

4.  Molecular mapping class II polymorphisms in the human major histocompatibility complex. II. DQ beta.

Authors:  A J MacMurray; J I Bell; D Denney; D Watling; L S Foster; H O McDevitt
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

5.  Association of a 9.2-kilobase Pvu II class I major histocompatibility complex restriction fragment length polymorphism with ankylosing spondylitis.

Authors:  D O McDaniel; R T Acton; B O Barger; W J Koopman; J D Reveille
Journal:  Arthritis Rheum       Date:  1987-08

6.  The association of HLA-B8 with visceral disease in systemic sclerosis.

Authors:  P Hughes; K Gelsthorpe; R W Doughty; N R Rowell; F D Rosenthal; I B Sneddon
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

7.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Authors:  V D Steen; D L Powell; T A Medsger
Journal:  Arthritis Rheum       Date:  1988-02

8.  High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients.

Authors:  J H Shero; B Bordwell; N F Rothfield; W C Earnshaw
Journal:  Science       Date:  1986-02-14       Impact factor: 47.728

9.  Histocompatibility antigens in progressive systemic sclerosis (scleroderma).

Authors:  N S Birnbaum; G P Rodnan; B S Rabin; S Bassion
Journal:  J Rheumatol       Date:  1977       Impact factor: 4.666

10.  Association of HLA antigen a9 with progressive systemic sclerosis (scleroderma).

Authors:  P J Clements; G Opelz; P I Terasaki; M R Mickey; D Furst
Journal:  Tissue Antigens       Date:  1978-04
View more
  29 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 2.  Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors:  C G Kallenberg
Journal:  Clin Rev Allergy       Date:  1994

3.  Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele.

Authors:  P G Vlachoyiannopoulos; U G Dafni; I Pakas; M Spyropoulou-Vlachou; C Stavropoulos-Giokas; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

4.  Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.

Authors:  G S Alarcón; J Calvo-Alén; G McGwin; A G Uribe; S M A Toloza; J M Roseman; M Fernández; B J Fessler; L M Vilá; C Ahn; F K Tan; J D Reveille
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

5.  Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study.

Authors:  N J McHugh; J Whyte; C Artlett; D C Briggs; C O Stephens; N J Olsen; N G Gusseva; P J Maddison; C M Black; K Welsh
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

6.  T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.

Authors:  M Kuwana; T A Medsger; T M Wright
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

7.  Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls.

Authors:  Frank C Arnett; Pravitt Gourh; Sanjay Shete; Chul W Ahn; Robert E Honey; Sandeep K Agarwal; Filemon K Tan; Terry McNearney; Michael Fischbach; Marvin J Fritzler; Maureen D Mayes; John D Reveille
Journal:  Ann Rheum Dis       Date:  2009-07-12       Impact factor: 19.103

8.  Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis.

Authors:  David R Karp; Nishanth Marthandan; Steven G E Marsh; Chul Ahn; Frank C Arnett; David S Deluca; Alexander D Diehl; Raymond Dunivin; Karen Eilbeck; Michael Feolo; Paula A Guidry; Wolfgang Helmberg; Suzanna Lewis; Maureen D Mayes; Chris Mungall; Darren A Natale; Bjoern Peters; Effie Petersdorf; John D Reveille; Barry Smith; Glenys Thomson; Matthew J Waller; Richard H Scheuermann
Journal:  Hum Mol Genet       Date:  2009-11-18       Impact factor: 6.150

9.  The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).

Authors:  M Kuwana; J Kaburaki; Y Okano; H Inoko; K Tsuji
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

10.  HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma).

Authors:  M Kuwana; Y Okano; J Kaburaki; H Inoko
Journal:  Ann Rheum Dis       Date:  1995-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.